NEW YORK & COPENHAGEN - Pfizer Inc. (NYSE: NYSE:PFE) and Genmab A/S (NASDAQ: NASDAQ:GMAB) have received full approval from the U.S. Food and Drug Administration (FDA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
This endorsement follows the positive outcomes from a global Phase 3 study, innovaTV 301, which met its primary endpoint by demonstrating an overall survival benefit for patients treated with TIVDAK compared to those receiving chemotherapy. The study showed a 30% reduction in the risk of death for patients on TIVDAK, with a median overall survival of 11.5 months, versus 9.5 months for those on chemotherapy.
The FDA's decision to grant full approval was influenced by the Priority Review Designation, which is assigned to drugs that may offer significant improvements in treatment over existing options. TIVDAK was initially given accelerated approval in September 2021, based on tumor response rates from the Phase 2 innovaTV 204 trial.
The safety profile of TIVDAK has been consistent with previous findings, showing no new safety concerns. However, the drug carries a boxed warning for ocular toxicity, and other warnings and precautions include peripheral neuropathy, hemorrhage, pneumonitis, severe cutaneous adverse reactions, and embryo-fetal toxicity.
As the first antibody-drug conjugate to show statistically significant prolonged overall survival data in this patient population, TIVDAK represents a notable advancement for women with advanced cervical cancer. The drug's approval is considered a significant milestone in meeting the high unmet need for effective treatments in the advanced stages of this disease.
InvestingPro Insights
Amid the significant milestone for Pfizer Inc. (NYSE: PFE) with the full FDA approval of TIVDAK, the company's financial metrics and market performance also provide critical insights for investors. Pfizer, a prominent player in the Pharmaceuticals industry, has demonstrated a commitment to shareholder returns, raising its dividend for 13 consecutive years, and maintaining dividend payments for 54 consecutive years, showcasing a strong track record of financial stability and investor confidence. The InvestingPro Tips highlight that Pfizer's net income is expected to grow this year, which could be indicative of the company's strong pipeline and innovative treatments like TIVDAK contributing to its financial health.
From a market perspective, Pfizer's current market capitalization stands at $144.85 billion, and it is trading at an adjusted price-to-earnings (P/E) ratio of 19.79 as of the last twelve months ending Q4 2023. Despite recent market volatility, the company pays a significant dividend to shareholders, with a current dividend yield of 6.55%. This commitment to shareholder value is further reinforced by the company's low price volatility, which may appeal to investors seeking stable returns in uncertain times.
For those looking to delve deeper into Pfizer's financials and market performance, InvestingPro Tips reveal that analysts are mixed on the company's outlook, with eight analysts revising their earnings downwards for the upcoming period. Nevertheless, analysts predict the company will remain profitable this year, which is supported by the company's profitability over the last twelve months. Investors interested in exploring additional insights can find more InvestingPro Tips at https://www.investing.com/pro/PFE, including a total of 12 tips to guide their investment decisions. Moreover, using the coupon code PRONEWS24, investors can enjoy an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to comprehensive analysis and data to inform their investment strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.